Literature DB >> 24865433

Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.

Florian Jentzmik1, Thomas J Schnoeller, Marcus V Cronauer, Julie Steinestel, Sandra Steffens, Friedemann Zengerling, Andreas Al Ghazal, Mark G Schrader, Konrad Steinestel, Andres J Schrader.   

Abstract

OBJECTIVES: To evaluate whether low testosterone levels or obesity, or both, are directly associated with tumor stage/grade in patients with clinically localized prostate cancer.
METHODS: Preoperative androgen serum levels (total and free testosterone), sex hormone-binding globulin, body mass index and waist circumference were assessed in 510 consecutive European Caucasian men treated with radical prostatectomy. Hormone levels and body mass index/waist circumference were correlated with patient- and tumor-specific characteristics using multivariable logistic regression analysis.
RESULTS: Even though we confirmed an inverse correlation between bodyweight and testosterone levels, only overweight - but not low testosterone - was associated with advanced disease and poor differentiation of prostate cancer. Using multivariate analyses, both body mass index ≥30 kg/m(2) and waist circumference >110 cm were associated with high-grade disease (Gleason score ≥8). A waist circumference >110 cm also correlated significantly with lymph node metastasis.
CONCLUSIONS: This is the first study showing that obesity, but not low serum testosterone levels, is significantly associated with high grade and metastatic disease in men diagnosed with clinically localized prostate cancer. The present findings suggest that low androgen levels at diagnosis, which used to be held responsible for the development of aggressive prostate cancer, is only an epiphenomenon of obesity rather than the cause of prostate cancer development and/or progression.
© 2014 The Japanese Urological Association.

Entities:  

Keywords:  grade; obesity; overweight; prostate cancer; prostatectomy; stage; testosterone

Mesh:

Substances:

Year:  2014        PMID: 24865433     DOI: 10.1111/iju.12494

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Serum 17β-estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer.

Authors:  Thomas J Schnoeller; Julie Steinestel; Friedemann Zengerling; Andres J Schrader; Florian Jentzmik
Journal:  World J Urol       Date:  2015-04-24       Impact factor: 4.226

2.  High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Maria Angela Cerruto; Matteo Brunelli; Salvatore Siracusano; Walter Artibani
Journal:  Asian J Androl       Date:  2020 May-Jun       Impact factor: 3.285

Review 3.  Linking obesogenic dysregulation to prostate cancer progression.

Authors:  Renea A Taylor; Jennifer Lo; Natasha Ascui; Matthew J Watt
Journal:  Endocr Connect       Date:  2015-12       Impact factor: 3.335

4.  Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy.

Authors:  Vincenzo Serretta; Alberto Abrate; Simone Siracusano; Cristina Scalici Gesolfo; Marco Vella; Fabrizio Di Maida; Antonina Cangemi; Giuseppe Cicero; Elisabetta Barresi; Chiara Sanfilippo
Journal:  Urol Ann       Date:  2018 Jul-Sep

5.  Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.

Authors:  Enrique Gómez-Gómez; Julia Carrasco-Valiente; Juan Pablo Campos-Hernández; Ana Maria Blanca-Pedregosa; Juan Manuel Jiménez-Vacas; Jesus Ruiz-García; Jose Valero-Rosa; Raul Miguel Luque; María José Requena-Tapia
Journal:  J Cell Mol Med       Date:  2018-11-18       Impact factor: 5.310

6.  Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Clara Cerrato; Alessandro Tafuri; Alberto Bianchi; Sebastian Gallina; Rossella Orlando; Nelia Amigoni; Riccardo Rizzetto; Alessandra Gozzo; Filippo Migliorini; Stefano Zecchini Antoniolli; Carmelo Monaco; Matteo Brunelli; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-07-06       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.